REVVITY, INC. RVTY
NYSE · XNYS · stock · Laboratory Analytical Instruments
Chart by TradingView
6/9
Piotroski F — financial health
3.86
Altman Z″ — distress risk · safe
13.6%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.9B | $241.2M | — | $509.4M | $7.3B |
| 2024 | $2.8B | $270.4M | — | $541.7M | $7.7B |
| 2023 | $2.8B | $693.1M | — | $198.0M | $7.9B |
| 2023 | $3.3B | $569.2M | $2.0B | $586.9M | $7.4B |
| 2022 | $3.8B | $943.2M | $2.4B | $1.3B | $7.1B |
| 2021 | $2.7B | $727.9M | $2.1B | $641.1M | $3.7B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Gonzales Anita | Vice President and CAO | 2026-06-15 | Tax withheld | 33 | $99.66 |
| MICHAS ALEXIS P | director | 2026-05-07 | Grant | 1,467 | — |
| Witney Frank | director | 2026-05-07 | Grant | 1,015 | — |
| Vandebroek Sophie V. | director | 2026-05-07 | Grant | 1,265 | — |
| Klobuchar Michael A | director | 2026-05-07 | Grant | 1,015 | — |
| Klobuchar Michael A | director | 2026-05-07 | Grant | 1,265 | — |
| Vandebroek Sophie V. | director | 2026-05-07 | Grant | 1,015 | — |
| MICHAS ALEXIS P | director | 2026-05-07 | Grant | 1,217 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.86 (safe)
- Working capital / assets 0.075
- Retained earnings / assets 0.498
- EBIT / assets 0.029
- Equity / liabilities 1.474
Source: SEC EDGAR filings · CIK 0000031791 · as of 2025-12-28. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.